J Cao1, X Sun1, X Zhang1, D Chen2. 1. Department of Urology, Xiangyang Central Hospital, Hospital Affiliated to Hubei University of Arts and Science, 39 Jingzhou Street, Xiangyang, 441021, Hubei, People's Republic of China. 2. Department of Urology, Xiangyang Central Hospital, Hospital Affiliated to Hubei University of Arts and Science, 39 Jingzhou Street, Xiangyang, 441021, Hubei, People's Republic of China. 1661471705@qq.com.
Abstract
PURPOSE: Although overexpression of the eukaryotic translation initiation factor 4E (eIF4E) is detected in patients with renal cell carcinoma (RCC) and associated with poor prognosis, the possible roles of eIF4E in RCC have not been revealed. METHODS: The effects of eIF4E inhibition on cell growth, migration, survival, chemo-/immunotherapy and eIF4E pathways via pharmacological inhibitor and genetic siRNA knockdown were analyzed in RCC cells. RESULTS: In this work, we demonstrate that eIF4E is critically involved in multiple biological functions of RCC. We firstly inhibited eIF4E activity by ribavirin in two cell lines (Caki-1 and ACHN) representing RCC metastasis models. We demonstrated that ribavirin inhibited proliferation and migration and induced apoptosis in RCC in a dose-dependent manner. We further confirmed that the inhibitory effects of ribavirin were attributed to its ability in inhibiting eIF4E-regulated protein translation and activity. eIF4E inhibition using siRNA knockdown mimicked ribavirin's effector in RCC cells. Importantly, eIF4E inhibition by both ribavirin and siRNA knockdown significantly sensitized RCC response to chemo- and immunotherapeutic agents in vitro as well as in vivo. CONCLUSIONS: Our findings clearly demonstrate the roles of eIF4E in RCC growth, survival, metastasis and resistance. Ribavirin is an antiviral drug, and its clinical efficacy is currently being investigated in the treatment of various cancers. Our findings support and provide a preclinical evidence for clinical trial for the combination of ribavirin with chemo-/immunotherapy in RCC.
PURPOSE: Although overexpression of the eukaryotic translation initiation factor 4E (eIF4E) is detected in patients with renal cell carcinoma (RCC) and associated with poor prognosis, the possible roles of eIF4E in RCC have not been revealed. METHODS: The effects of eIF4E inhibition on cell growth, migration, survival, chemo-/immunotherapy and eIF4E pathways via pharmacological inhibitor and genetic siRNA knockdown were analyzed in RCC cells. RESULTS: In this work, we demonstrate that eIF4E is critically involved in multiple biological functions of RCC. We firstly inhibited eIF4E activity by ribavirin in two cell lines (Caki-1 and ACHN) representing RCC metastasis models. We demonstrated that ribavirin inhibited proliferation and migration and induced apoptosis in RCC in a dose-dependent manner. We further confirmed that the inhibitory effects of ribavirin were attributed to its ability in inhibiting eIF4E-regulated protein translation and activity. eIF4E inhibition using siRNA knockdown mimicked ribavirin's effector in RCC cells. Importantly, eIF4E inhibition by both ribavirin and siRNA knockdown significantly sensitized RCC response to chemo- and immunotherapeutic agents in vitro as well as in vivo. CONCLUSIONS: Our findings clearly demonstrate the roles of eIF4E in RCC growth, survival, metastasis and resistance. Ribavirin is an antiviral drug, and its clinical efficacy is currently being investigated in the treatment of various cancers. Our findings support and provide a preclinical evidence for clinical trial for the combination of ribavirin with chemo-/immunotherapy in RCC.
Entities:
Keywords:
Protein translation; RCC; Ribavirin; eIF4E
Authors: Filippa Pettersson; Christina Yau; Monica C Dobocan; Biljana Culjkovic-Kraljacic; Hélène Retrouvey; Hélène Retrouvay; Rachel Puckett; Ludmila M Flores; Ian E Krop; Caroline Rousseau; Eftihia Cocolakis; Katherine L B Borden; Christopher C Benz; Wilson H Miller Journal: Clin Cancer Res Date: 2011-03-17 Impact factor: 12.531
Authors: Erick De la Cruz-Hernandez; Jose Luis Medina-Franco; Jaenai Trujillo; Alma Chavez-Blanco; Guadalupe Dominguez-Gomez; Enrique Perez-Cardenas; Aurora Gonzalez-Fierro; Lucia Taja-Chayeb; Alfonso Dueñas-Gonzalez Journal: Oncol Rep Date: 2015-02-25 Impact factor: 3.906
Authors: Michael G Kharas; Jonathan A Deane; Stephane Wong; Karen R O'Bosky; Naomi Rosenberg; Owen N Witte; David A Fruman Journal: Blood Date: 2004-02-19 Impact factor: 22.113
Authors: Hans-Guido Wendel; Ricardo L A Silva; Abba Malina; John R Mills; Hong Zhu; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga; Julie Teruya-Feldstein; Jerry Pelletier; Scott W Lowe Journal: Genes Dev Date: 2007-11-30 Impact factor: 11.361
Authors: Klaudia K Brodaczewska; Cezary Szczylik; Michal Fiedorowicz; Camillo Porta; Anna M Czarnecka Journal: Mol Cancer Date: 2016-12-19 Impact factor: 27.401